Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of Age: A Phase 1/2 Randomized Trial
Xavier Saez-Llorens, Ximena Norero,Marisa Marcia Mussi-Pinhata,Kathia Luciani,Ignacio Salamanca de la Cueva, Javier Diez-Domingo,Eduardo Lopez-Medina,Cristina Epalza, Jerzy Brzostek, Henryk Szymanski, Francois D. Boucher, Benhur S. Cetin, Tirza De Leon,Ener Cagri Dinleyici, Miguel Angel Marin Gabriel,Tolga Ince, Mercedes Macias-Parra,Joanne M. Langley, Federico Martinon-Torres,Mika Ramet,Ernest Kuchar,Jorge Pinto,Thanyawee Puthanakit, Fernando Baquero-Artigao, Guido Castelli Gattinara, Jose Manuel Merino Arribas, Jose Tomas Ramos Amador,Leszek Szenborn,Bruce Tapiero,Evan J. Anderson,James D. Campbell, Saul N. Faust, Vanja Nikic, Yingjun Zhou, Wenji Pu,Damien Friel,Ilse Dieussaert,Antonio Gonzalez Lopez, Roderick McPhee,Sonia K. Stoszek,Nicolas Vanhoutte JOURNAL OF INFECTIOUS DISEASES（2024）
Key words
ChAd155,RSV,immunogenicity,infant,vaccine-associated enhanced respiratory disease
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper